Compare Ryanair Holdings plc (RYAAY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs TransMedics Group Inc — how do they compare? Ryanair Holdings plc trades at $53.11 (market cap $27.11B), while TransMedics Group Inc trades at $77.75 (market cap $2.74B). The key difference: Ryanair Holdings plc is far larger — about 9.9× TransMedics Group Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and TransMedics Group Inc for 24 Days on average.
| RYAAY | TMDX | |
|---|---|---|
Market Cap | $27.11B | $2.74B |
Volume | 2,427,380 | 949,331 |
Sector | Industrials | Health |
52-Week High | $73.82 | $150.42 |
52-Week Low | $51.95 | $61.99 |
Typical Hold Time | 72 Days | 24 Days |
Enterprise Value | $24.18B | $3.13B |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $53.05, down 5.27% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with $13.95B revenue, 12.13% net margin, and attractive valuation at 13.43 P/E. Recent earnings show mixed results with Q2 2026 missing expectations, while analysts maintain 64.71% buy rating. The company faces headwinds from fuel costs and Boeing MAX 10 certification delays, but maintains robust cash flow and balance sheet strength.
RYAAY presents a compelling value opportunity with solid profitability and growth prospects, though near-term volatility from oil prices and operational challenges warrants caution. The stock's current discount to historical valuations combined with strong market position supports long-term upside potential for patient investors.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
